Skip to main content

cancer immunotherapy Archives

Nanoparticles boost anti-cancer immunity

Aug. 16, 2022—An ingenious targeted nanoparticle approach developed by Vanderbilt researchers reduced tumor burden in a model of ovarian cancer.

Read more


Couple’s gift helps support immunotherapy research

Aug. 11, 2022—Luke and Susan Simons have endowed a new directorship that will support research so that more people can benefit from immunotherapies.

Read more


Breast cancer cells ‘steal’ nutrients from immune cells: study

Apr. 1, 2021—Triple-negative breast cancer cells engage in a “glutamine steal” — outcompeting T cells for the nutrient glutamine and impairing their ability to kill tumor cells, Vanderbilt researchers have discovered.

Read more


A “torque” for tumor blood vessels

Aug. 20, 2020—Vanderbilt scientists have discovered a new target for normalizing tumor blood vessels to improve cancer immunotherapies.

Read more


Potential new cancer target

Jun. 4, 2020—Vanderbilt researchers have discovered the involvement of a certain type of adenosine receptor in mediating signaling that supports tumor growth and metastasis.

Read more


Patient’s cancer treatment includes new immunotherapy

Feb. 27, 2020—Dona Potter, 87, rode Harleys and drove 18-wheelers back when men dominated the open highways, and she is still defying expectations.

Read more


New prostate cancer treatment concept

Aug. 22, 2019—Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer.

Read more


Encephalitis identified as rare toxicity of immunotherapy treatment

Jul. 22, 2019—Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.

Read more


Discovery points to new cancer immunotherapy option

Feb. 21, 2019—An international team involving Vanderbilt researchers has discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.

Read more


GE Healthcare, Vanderbilt University Medical Center partner for safer, more precise immunotherapy cancer treatment

Jan. 7, 2019—GE Healthcare and Vanderbilt University Medical Center (VUMC) today announced a five-year partnership to enable safer and more precise cancer immunotherapies.

Read more


Breast cancer-killing RIG

Dec. 13, 2018—A compound that activates a virus-sensing receptor has potent therapeutic effects in a mouse model of breast cancer.

Read more


Immunotherapies linked to specific heart complications

Nov. 15, 2018—In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more